معرفی
Professor Jose Polo is the inaugural Director of the Adelaide Centre for Epigenetics (ACE) and group leader at the South Australian Immunogenomics Cancer Institute (SAiGENCI) at the University of Adelaide. He holds appointments in the Faculty of Health and Medical Sciences and School of Biomedicine. His research focuses on epigenetic mechanisms governing cell identity, reprogramming, and cancer. Key achievements include co-founding Mogrify Ltd to translate reprogramming technologies into therapies and pioneering induced trophoblast stem cell (iTSC) research.
Education: Biochemistry degree from Buenos Aires University, PhD from Albert Einstein College of Medicine (2008). Postdoctoral training at Harvard Stem Cell Institute (2008–2011). Established independent research groups at Monash University (2011–2021) and now at the University of Adelaide since 2021.
Research Interests: Epigenetic regulation of pluripotency, cellular reprogramming, cancer initiation/progression, and synthetic cell biology. Techniques include stem cell models, genomic approaches (ChIP, CUT&RUN, single-cell omics), and novel methods like TINC for protein complex analysis.
Grants & Awards: Over 15 grants including NHMRC, ARC, and industry partnerships. Recognitions include the Metcalf Award, Victorian Tall Poppy Award, and Scrip Innovation Award.
Advising & Labs: Supervised over 20 PhD/Masters students and postdocs. Current lab projects include iBlastoid development, iTSC models for placental research, and epigenetic mechanisms in cancer.
